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Summary
Background Haemophilus inﬂ uenzae type b (Hib) conjugate vaccine, delivered as a three-dose series without a booster, 
was introduced into the childhood vaccination programme in Kenya in 2001. The duration of protection and need for 
a booster dose are unknown. We aimed to assess vaccine eﬀ ectiveness, the impact of the vaccine on nasopharyngeal 
carriage, and population immunity after introduction of conjugate Hib vaccine in infancy without a booster dose 
in Kenya.
Methods This study took place in the Kiliﬁ  Health and Demographic Surveillance System (KHDSS), an area of Kenya 
that has been monitored for vital events and migration every 4 months since 2000. We analysed sterile site cultures 
for H inﬂ uenzae type b from children (aged ≤12 years) admitted to the Kiliﬁ  County Hospital (KCH) from Jan 1, 2000, 
through to Dec 31, 2014. We determined the prevalence of nasopharyngeal carriage by undertaking cross-sectional 
surveys in random samples of KHDSS residents (of all ages) once every year from 2009 to 2012, and measured Hib 
antibody concentrations in ﬁ ve cross-sectional samples of children (aged ≤12 years) within the KHDSS (in 1998, 2000, 
2004–05, 2007, and 2009). We calculated incidence rate ratios between the prevaccine era (2000–01) and the routine-
use era (2004–14) and deﬁ ned vaccine eﬀ ectiveness as 1 minus the incidence rate ratio, expressed as a percentage.
Findings 40 482 children younger than 13 years resident in KHDSS were admitted to KCH between 2000 and 2014, 
38 206 (94%) of whom had their blood cultured. The incidence of invasive H inﬂ uenzae type b disease in children 
younger than 5 years declined from 62·6 (95% CI 46·0–83·3) per 100 000 in 2000–01 to 4·5 (2·5–7·5) per 100 000 in 
2004–14, giving a vaccine eﬀ ectiveness of 93% (95% CI 87–96). In the ﬁ nal 5 years of observation (2010–14), only one 
case of invasive H inﬂ uenzae type b disease was detected in a child younger than 5 years. Nasopharyngeal H inﬂ uenzae 
type b carriage was detected in one (0·2%) of 623 children younger than 5 years between 2009 and 2012. In the 2009 
serosurvey, 92 (79%; 95% CI 70–86) of 117 children aged 4–35 months had long-term protective antibody 
concentrations.
Interpretation In this region of Kenya, use of a three-dose primary series of Hib vaccine without a booster dose has 
resulted in a signiﬁ cant and sustained reduction in invasive H inﬂ uenzae type b disease. The prevalence of 
nasopharyngeal carriage is low and the proﬁ le of Hib antibodies suggests that protection wanes only after the age at 
greatest risk of disease. Although continued surveillance is important to determine whether eﬀ ective control persists, 
these ﬁ ndings suggest that a booster dose is not currently required in Kenya.
Funding Gavi, the Vaccine Alliance, Wellcome Trust, European Society for Paediatric Infectious Diseases, and National 
Institute for Health Research.
Copyright © Hammitt et al. Open Access article distributed under the terms of CC BY.
Introduction
Inclusion of Haemophilus inﬂ uenzae type b (Hib) 
conjugate vaccine in the routine infant immunisation 
programme has led to tremendous reductions in 
childhood H inﬂ uenzae type b morbidity and mortality 
in both developed and developing countries.1,2 Hib 
vaccine was introduced into the Kenyan childhood 
Expanded Program on Immunization (EPI) in 
November, 2001, as a three-dose series administered at 
6, 10, and 14 weeks of age. Within 3 years of introduction, 
invasive H inﬂ uenzae type b disease had decreased to 
12% of its baseline level.3 A booster dose of Hib vaccine 
is not included in the Kenyan EPI schedule, nor in the 
schedules of 72 (92%) of 78 low-income and lower-
middle-income countries.4
In the UK, 10 years after the introduction of the Hib 
primary vaccination, waning levels of antibody to 
polyribosylribitol phosphate (PRP)—an H inﬂ uenzae 
type b polysaccharide capsule component—as well as 
persistence of H inﬂ uenzae type b nasopharyngeal 
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colonisation and rising rates of invasive disease, 
prompted introduction of a booster dose of Hib vaccine 
for children aged 12–15 months in 2006.5,6 The 
Government of Mexico also introduced a booster dose of 
Hib vaccine 9 years after launching the primary 
vaccination programme, in part because of waning anti-
PRP antibodies in children aged 12–59 months.7 
However, persistently low incidence of H inﬂ uenzae 
type b meningitis in the western region of The Gambia 
more than a decade after Hib vaccine introduction 
shows that the disease can be adequately controlled in 
the absence of a booster dose.8
The long-term eﬀ ectiveness of a primary series of Hib 
vaccine in infancy can be inferred from incidence of 
invasive H inﬂ uenzae type b disease, nasopharyngeal 
carriage prevalence, and seroepi demiological data from 
the general population. Hib vaccination induces serum 
antibody production and reduces the nasopharyngeal 
carriage prevalence of H inﬂ uenzae type b, thereby 
diminishing the risk of invasive disease. Reductions in 
carriage also reduce transmission of Hib between 
individuals. This contributes to herd protection, but also 
limits the opportunity for intermittent natural boosting 
of serological immunity. The pattern of H inﬂ uenzae 
type b serological immunity in diﬀ erent age groups 
across time and the persistence of H inﬂ uenzae type b 
serological immunity throughout the years of highest 
risk for H inﬂ uenzae type b disease are likely to be 
important determinants of vaccine eﬀ ectiveness beyond 
the primary vaccination period.
There is equipoise in the scientiﬁ c community 
regarding the need for a booster dose of Hib vaccine to 
control disease in the long term.9 Herein we report 
vaccine eﬀ ectiveness, the impact of the vaccine on 
nasopharyngeal carriage of H inﬂ uenzae type b, and 
population immunity to H inﬂ uenzae type b in the 
13 years after introduction of conjugate Hib vaccine in 
infancy without a booster dose in Kenya.
Methods
Population
This surveillance study took place in the Kiliﬁ  Health 
and Demographic Surveillance System (KHDSS), a 
rural community on the Kenyan coast covering an area 
of 891 km².10 A census of the KHDSS in 2000 deﬁ ned 
the resident population and, since 2000, ﬁ eldworkers 
have been monitoring migration events by visiting 
every participating household roughly every 4 months. 
The annual population was 199 732 in 2000, 239 396 in 
2007, and 279 877 in 2014. The population is served by 
several government-funded health centres and by one 
government hospital, Kiliﬁ  County Hospital (KCH). 
Among women attending antenatal care at KCH, the 
prevalence of HIV infection ranged between 2·4% and 
4·6% during 2005–13, with a general downwards trend. 
The prevalence of HIV in children in Kenya was 
estimated in 2012 to be 0·9% nationally.11
On Nov 1, 2001, the Government of Kenya introduced 
tetanus-toxoid-conjugated Hib vaccine as part of a 
pentavalent formulation in which lyophilised Hib vaccine 
(Hiberix; GlaxoSmithKline, Rixensart, Belgium) was 
resuspended in the diphtheria, tetanus, whole-cell 
pertussis, hepatitis B vaccine (Tritanrix, GlaxoSmithKline). 
The ﬁ rst children eligible to receive a 6-week dose of this 
Research in context
Evidence before this study
We searched PubMed with the terms “Hib”, “Haemophilus 
inﬂ uenzae type b”, “vaccine”, “eﬀ ectiveness”, “seroepidemiology”, 
“anti-PRP”, “booster”, “cross reactive”, “carriage”, and 
“colonization” for articles published in any language before 
May 31, 2015. To identify additional publications we searched 
the reference lists of retrieved articles. More than a decade after 
conjugate Haemophilus inﬂ uenzae type b (Hib) vaccines became 
available, only 2% of the global H inﬂ uenzae type b disease 
burden was being prevented by vaccination. In 2001, Gavi, the 
Vaccine Alliance, oﬀ ered ﬁ nancial support for the introduction of 
Hib vaccine in developing countries, and Kenya became one of 
the ﬁ rst African countries to include Hib vaccine in the national 
immunisation schedule. Like the vast majority of low-income 
and lower-middle-income countries, Kenya used a three-dose 
primary series of Hib vaccine, without a booster dose. 
A three-dose schedule without a booster is highly eﬀ ective in 
reducing the burden of H inﬂ uenzae type b disease in the short 
term; however, whether a booster dose is required to achieve 
sustained disease control is unclear. Although data from some 
countries have prompted the addition of a booster dose, other 
data show good control of H inﬂ uenzae type b disease in the 
absence of a booster. The need for a booster dose of Hib vaccine 
is probably aﬀ ected by local epidemiology and factors such as the 
potential for natural boosting.
Added value of this study
This study provides new data documenting the near 
elimination of invasive H inﬂ uenzae type b disease in Kiliﬁ , 
Kenya, in the 12 years after introduction of vaccine into the 
routine infant vaccination schedule without a booster dose. 
The detailed seroepidemiology work before and after vaccine 
introduction shows that the vaccine has led to improvements 
in population immunity in the youngest, highest-risk age 
groups without compromising immunity in older children.
Implications of all the available evidence
This study delivers compelling evidence of the long-term 
operational impact of a three-dose primary series of Hib vaccine 
in a low-income country and provides a clear answer to a 
pertinent policy question in Kenya: a booster dose of vaccine is 
not currently needed to control H inﬂ uenzae type b disease. 
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pentavalent vaccine were born on Sept 20, 2001, and 
would have been eligible to receive their third dose at the 
end of December, 2001.
The protocol was approved by the Oxford Tropical 
Ethical Review Committee (No. 30-10) and the Kenya 
National Ethical Review Committee (SSC1433). Parents 
or guardians of all study participants provided written 
informed consent.
Assessment of vaccine eﬀ ectiveness
To assess vaccine eﬀ ectiveness, we determined the 
prevalence of invasive H inﬂ uenzae type b disease in 
children aged 12 years or younger admitted to KCH 
between Jan 1, 2000, and Dec 31, 2014. Blood samples are 
routinely taken for culture at the time of admission (except 
for trauma patients or patients admitted for elective 
surgery). Blood was cultured using an automated BACTEC 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Age <5 years
Admissions 3660 3591 3282 2776 2716 2317 2455 2130 1986 2131 1905 1642 1494 1001 1473
With blood culture 3613
(99%)
3533
(98%)
3200
(98%)
2710
(98%)
2631
(97%)
2219
(96%)
2366
(96%)
1991
(93%)
1841
(93%)
1996
(94%)
1747
(92%)
1528
(93%)
1331
(89%)
904
(90%)
1335
(91%)
With lumbar 
puncture
939
(26%)
866
(24%)
936
(29%)
578
(21%)
351
(13%)
482
(21%)
693
(28%)
611
(29%)
553
(28%)
548
(26%)
532
(28%)
433
(26%)
410
(27%)
260
(26%)
390
(26%)
With probable 
bacterial meningitis
33
(1%)
40
(1%)
52
(2%)
24
(1%)
20
(1%)
24
(1%)
25
(1%)
26
(1%)
18
(1%)
16
(1%)
18
(1%)
18
(1%)
11
(1%)
11
(1%)
5
(<1%)
Culture-conﬁ rmed 
H inﬂ uenzae disease
24
(<1%)
30
(<1%)
21
(<1%)
22
(<1%)
4
(<1%)
5
(<1%)
2
(<1%)
2
(<1%)
5
(<1%)
2
(<1%)
1
(<1%)
0 3
(<1%)
2
(<1%)
3
(<1%)
Types a, c, d, e, f 2
(8%)
1
(3%)
1
(5%)
0 1
(25%)
1
(20%)
0 1
(50%)
2
(40%)
0 0 0 2
(67%)
1
(50%)
1
(33%)
Non-capsular 3
(13%)
1
(3%)
3
(14%)
4
(18%)
0 1
(20%)
0 0 1
(20%)
0 1
(100%)
0 1
(33%)
0 2
(67%)
Type b 19
(79%)
28
(93%)
17
(81%)
18
(82%)
3
(75%)
3
(60%)
2
(100%)
1
(50%)
2
(40%)
2
(100%)
0 0 0 1
(50%)
0
H inﬂ uenzae 
type b cultured 
in CSF
4
(21%)
13
(46%)
8
(47%)
8
(44%)
1
(33%)
1
(33%)
0 0 1
(50%)
1
(50%)
0 0 0 0 0
Age 
<24 months
16
(84%)
19
(68%)
10
(59%)
10
(56%)
2
(67%)
1
(33%)
0 1
(100%)
1
(50%)
2
(100%)
0 0 0 1
(100%)
0
Boys 7
(37%)
15
(54%)
6
(35%)
7
(39%)
2(67%) 1
(33%)
1
(50%)
1
(100%)
0 1
(50%)
0 0 0 1
(100%)
0
Died during the 
episode
3
(16%)
8
(29%)
5
(29%)
6
(33%)
0 1
(33%)
0 1
(100%)
1
(50%)
0 0 0 0 1
(100%)
0
Age 5–12 years
Admissions 459 398 377 416 373 425 419 369 356 395 436 413 324 283 480
With blood culture 448
(98%)
378
(95%)
361
(96%)
394
(95%)
328
(88%)
371
(87%)
376
(90%)
326
(88%)
308
(87%)
331
(84%)
380
(87%)
347
(84%)
274
(85%)
226
(80%)
413
(86%)
With lumbar 
puncture
74
(16%)
55
(14%)
68
(18%)
54
(13%)
41
(11%)
37
(9%)
56
(13%)
44
(12%)
50
(14%)
46
(12%)
88
(20%)
65
(16%)
71
(22%)
81
(29%)
96
(20%)
With probable 
bacterial meningitis
7
(2%)
5
(1%)
6
(2%)
10
(2%)
5
(1%)
1
(<1%)
1
(<1%)
5
(1%)
4
(1%)
3
(1%)
4
(1%)
3
(1%)
1
(<1%)
4
(1%)
1
(<1%)
Culture-conﬁ rmed 
H inﬂ uenzae disease
1
(<1%)
2
(<1%)
2
(<1%)
2
(<1%)
1
(<1%)
1
(<1%)
1
(<1%)
0 0 1
(<1%)
1
(<1%)
1
(<1%)
0 0 1
(<1%)
Types a, c, d, e, f 0 0 1
(50%)
0 0 0 1
(100%)
0 0 0 0 0 0 0 0
Non-capsular 1
(100%)
0 0 0 0 1
(100%)
0 0 0 0 0 1
(100%)
0 0 1
(100%)
Type b 0 2
(100%)
1
(50%)
2
(100%)
1
(100%)
0 0 0 0 1
(100%)
1
(100%)
0 0 0 0
H inﬂ uenzae 
type b cultured 
in CSF
0 1
(50%)
1
(100%)
1
(50%)
1
(100%)
0 0 0 0 1
(100%)
1
(100%)
0 0 0 0
Boys 0 1
(50%)
1
(100%)
1
(50%)
0 0 0 0 0 1
(100%)
1
(100%)
0 0 0 0
Died during the 
episode
0 1
(50%)
1
(100%)
1
(50%)
0 0 0 0 0 0 0 0 0 0 0
Data are N and n (%). CSF=cerebrospinal ﬂ uid.
Table 1: Invasive Haemophilus inﬂ uenzae disease in children aged 0–12 years in the Kiliﬁ  Health and Demographic Surveillance System admitted to the Kiliﬁ  County Hospital, 2000–14 
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instrument (BD Diagnostics, Franklin Lakes, NJ, USA). 
From 1998 to 2014, with the exception of a brief change in 
practice in 2004–05, the clinical indications for lumbar 
puncture were impaired consciousness or meningism in 
children younger than 5 years, prostration in children 
younger than 3 years, seizures (other than febrile seizures) 
in children younger than 2 years, and suspicion of sepsis 
in children younger than 60 days. Cerebrospinal ﬂ uid 
(CSF) was cultured on horse blood and chocolate agar. 
Beginning in 2003, HIV testing was done on the blood of 
children admitted to KCH according to the Kenya national 
policy for paediatric hospital admissions, using two rapid 
antibody tests. Treatment for all disorders was according to 
WHO guidelines at the time of admission.
Isolates of H inﬂ uenzae from sterile-site cultures were 
identiﬁ ed by colony morphology, Gram stain, and X and 
V factor dependence at the KEMRI-Wellcome Trust 
laboratory, located adjacent to KCH. Capsular type was 
identiﬁ ed by PCR using either the cap locus (done by the 
Haemophilus Reference Unit/WHO Collaborating 
Centre for Haemophilus inﬂ uenzae, Respiratory and 
Systemic Infection Laboratory, Health Protection Agency 
Centre for Infections, London, UK, for isolates collected 
in 2000–04) or the bexA locus (done by the 
KEMRI-Wellcome Trust laboratory in Kiliﬁ , Kenya, for 
isolates collected in 2005–13).12 We deﬁ ned a case of 
invasive H inﬂ uenzae type b disease as isolation of type b 
H inﬂ uenzae from a sterile-site culture in a child aged 
12 years or younger admitted to KCH.
Assessment of nasopharyngeal carriage
We investigated nasopharyngeal carriage of H inﬂ uenzae 
type b by undertaking annual cross-sectional surveys of a 
sample of KHDSS residents of all ages, selected at 
random from the KHDSS population register once every 
year from 2009 to 2012, as described elsewhere.13 Isolates 
of H inﬂ uenzae type b from nasopharyngeal swabs were 
identiﬁ ed in the same way as for sterile-site samples.
Assessment of serological immunity
We assessed serological immunity to H inﬂ uenzae 
type b in ﬁ ve cross-sectional samples of children aged 
12 years or younger within the study area, consisting of 
four convenience samples from the Junju, Ngerenya, 
and Chonyi locations in Kiliﬁ  County during 1998, 
2000, 2004–05, and 2007,14,15 and an age-stratiﬁ ed sample 
(50 children in each of ten age strata: 0 years, 1 year, 
2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 
8–9 years, and 10–14 years) selected at random using 
Stata (version 10.1) from each age strata from the 
population register of the KHDSS in 2009.
Serum samples were stored at –70°C until they were 
tested using an ELISA for antibodies to PRP. ELISA was 
done at the WHO Pneumococcal Reference Laboratory, 
Institute of Child Health, London, UK. Methods were as 
documented elsewhere,16 but with the following alteration: 
HbOHA antigen (National Institute for Biological 
Standards and Controls, Hertfordshire, UK) was used at 
3 mg/mL. Test, control, and reference (lot 1983; US Food 
and Drug Administration) serum samples were incubated 
at 37°C for 1 h. The antibody-binding reaction was 
monitored by absorbance readings at 410 nm and 630 nm. 
We determined anti-PRP concentrations by referring to a 
standard curve generated from the reference wells using 
four-parameter sigmoid curve ﬁ tting. Median values were 
reported for test serum samples displaying non-
parallelism to this curve. Values below the lower limit of 
quantitation (0·09 mg/mL) were reported as 0·05 mg/mL.
Statistical analysis
For population-based analyses, we designated Jan 1, 
2000, through to Dec 31, 2001, as the prevaccine era and 
Jan 1, 2004, through to Dec 31, 2014, as the routine-use 
era, to allow time for suﬃ  cient vaccine uptake, given 
that the Hib vaccine was introduced without a catch-up 
campaign. We calculated the incidence of invasive 
H inﬂ uenzae type b disease as the number of KHDSS 
residents admitted to KCH and conﬁ rmed by sterile-site 
culture to have H inﬂ uenzae type b infection, divided by 
the resident population at the midpoint of each 
observation period. We calculated the incidence of 
H inﬂ uenzae type b meningitis as the number of KHDSS 
residents admitted to KCH with culture-conﬁ rmed 
H inﬂ uenzae type b (from any sterile site) who met a 
deﬁ nition of probable meningitis (CSF white cell count 
≥50 × 10⁶ cells/L or a ratio of CSF glucose to plasma 
glucose of <0·1), divided by the resident population at 
the midpoint of each observation period. We calculated 
the incidence rate ratio (IRR) by using Poisson 
regression for speciﬁ c age groups and observation 
Figure 1: Incidence of invasive Haemophilus inﬂ uenzae type b disease in children younger than 5 years in the 
Kiliﬁ  Health and Demographic Surveillance System, 2000–14
Hib vaccine was introduced in November, 2001. Error bars show 95% CI.
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periods. We calculated vaccine eﬀ ectiveness as 1 minus 
the IRR, expressed as a percentage.
We excluded data from 2004–05 from calculations 
related to meningitis because a transient change in 
lumbar puncture clinical practice occurred during this 
period, and we did not analyse meningitis data after 
2010 because pneumococcal conjugate vaccine was 
introduced in 2011, which was expected to reduce the 
incidence of probable meningitis. We categorised PRP 
antibody concentrations according to putative threshold 
protective con centrations, and calculated geometric 
mean con centrations by year and age category. Pre-2009 
serosurveys did not include children aged 13 years or 
older, so we excluded data from children who were 
13 years or older in 2009 from the serological immunity 
analyses. We present the decline in PRP antibody 
concentration and reverse cumulative distribution 
curves according to age category and year.
We did all statistical analyses using Stata, versions 11.2 
and 12.0.
Role of the funding source
The funders of the study had no role in study design; in 
the collection, analysis, and interpretation of data; or the 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
40 482 children younger than 13 years resident in 
KHDSS were admitted to KCH between 2000 and 2014, 
38 206 (94%) of whom had their blood cultured. Although 
the number of cases of invasive H inﬂ uenzae type b 
disease declined after vaccine introduction, the site of 
culture, sex of patients, and syndrome-speciﬁ c mortality 
did not change substantially between the pre-vaccine 
and routine-use eras (table 1). In children younger than 
5 years, the median age of infection with H inﬂ uenzae 
type b was 10 months (IQR 5–24) in the prevaccine era 
and 10·5 months (4–23) in the routine-use era. HIV 
status was determined for 25 (68%) of the 37 KHDSS 
children with invasive H inﬂ uenzae type b disease from 
2003 to 2014. Four (16%) of the 25 children with 
H inﬂ uenzae type b disease had HIV infection (three in 
2003 and one in 2008). For comparison, HIV prevalence 
in all paediatric admissions to KCH in 2005–14 was 
4·3% (807 of 18 767 admissions in whom HIV results 
were available).
Age <2 years Age <5 years Age 5–12 years
N Incidence (95% CI) N Incidence (95% CI) N Incidence (95% CI)
Invasive H inﬂ uenzae type b disease
2000–01 35 117·1 (81·6–162·9) 47 62·6 (46·0–83·3) 2 4·0 (0·5–14·6)
2002–03 25 79·4 (51·4–117·2) 34 44·6 (31·0–61·8) 3 2·9 (0·6–8·6)
2004–14 11 8·6 (4·3–15·3) 14 4·5 (2·5–7·5) 3 1·7 (0·3–4·8)
2004–05 5 14·5 (4·7–33·8) 6 7·1 (2·6–15·4) 1 1·9 (0·1–10·3)
2006–09 5 6·7 (2·2–15·7) 7 3·9 (1·6–8·0) 1 1·6 (0·0–8·8)
2010–14 1 5·1 (0·1–28·3) 1 2·1 (0·1–11·5) 1 1·6 (0·0–8·6)
Incidence rate ratio
2000–01 vs 2002–03 ·· 0·67 (0·41–1·13) ·· 0·71 (0·46–1·10) ·· 0·73 (0·12–4·34)
2000–01 vs 2004–14 ·· 0·07 (0·04–0·14) ·· 0·07 (0·04–0·13) ·· 0·41 (0·07–2·44)
H inﬂ uenzae type b meningitis
2000–01 14 46·8 (25·6–78·6) 17 22·7 (13·2–36·3) 1 2·0 (0·5–11·2)
2002–03 12 38·1 (19·7–66·6) 15 19·1 (10·7–31·4) 1 2·0 (0·1–11·0)
2006–10 2 5·3 (0·7–19·2) 2 2·2 (0·3–7·9) 2 1·6 (0·2–5·6)
Incidence rate ratio
2000–01 vs 2002–03 ·· 0·81 (0·38–1·76) ·· 0·84 (0·42–1·68) ·· 0·97 (0·06–15·57)
2000–01 vs 2006–10 ·· 0·11 (0·03–0·50) ·· 0·09 (0·02–0·42) ·· 0·77 (0·07–8·54)
Probable bacterial meningitis
2000–01 61 204·1 (156·1–262·2) 73 97·3 (76·3–122·3) 15 15·3 (8·6–25·3)
2002–03 67 212·9 (165·0–270·3) 76 96·5 (76·0–120·8) 17 16·6 (9·7–26·6)
2006–10 80 85·4 (67·7–106·3) 103 45·3 (37·0–55·0) 17 5·5 (3·2–8·8)
Incidence rate ratio
2000–01 vs 2002–03 ·· 1·04 (0·74–1·48) ·· 0·99 (0·72–1·37) ·· 1·08 (0·54–2·17)
2000–01 vs 2006–10 ·· 0·41 (0·30–0·58) ·· 0·47 (0·35–0·63) ·· 0·36 (0·18–0·72)
N is the number of children with the disease during the corresponding timeframe.
Table 2: Incidence (per 100 000) of invasive Haemophilus inﬂ uenzae type b disease and meningitis, and probable bacterial meningitis, in children aged 
0–12 years in the Kiliﬁ  Health and Demographic Surveillance System, 2000–14
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The mean annual incidence of invasive H inﬂ uenzae 
type b disease in children younger than 5 years in Kiliﬁ  
was 62·6 per 100 000 (95% CI 46·0–83·3) in the pre-
vaccine era (2000–01) and 4·5 per 100 000 (2·5–7·5) in 
the routine-use era (2004–14; ﬁ gure 1), which translates 
to a vaccine eﬀ ectiveness of 93% (95% CI 87–96; table 2). 
Incidences of invasive H inﬂ uenzae type b disease and 
meningitis in the early introduction era (2002–03) were 
signiﬁ cantly higher than in later periods in children 
younger than 5 years, but rates of invasive H inﬂ uenzae 
type b disease were similar in diﬀ erent periods of 
routine use (table 2). Incidence of invasive H inﬂ uenzae 
type b disease in children aged 5–12 years was low in the 
prevaccine era and remained low in the routine-use era 
(table 2). In the routine-use era, 13 of the 17 cases of 
invasive H inﬂ uenzae type b disease occurred in children 
younger than 36 months (the age before which 
serological immunity starts to decline and a comparable 
metric to that presented in the ﬁ rst Kiliﬁ  analysis3). The 
incidence of non-type-b invasive H inﬂ uenzae disease 
(ie, serotype replacement disease) did not increase after 
introduction of the Hib vaccine (IRR in children aged 
<5 years, 2000–01 vs 2004–14, was 0·71 (95% CI 
0·19–2·61; table 1).
A previous study17 showed that nasopharyngeal carriage 
of H inﬂ uenzae type b in children younger than 5 years 
was 1·7% in 2004, 3 years after Hib vaccine introduction. 
We obtained nasopharyngeal swabs from 2031 KHDSS 
residents in the four annual cross-sectional naso-
pharyngeal swab surveys we did in 2009–12. One (0·2%; 
identiﬁ ed in the 2012 survey) of 623 children younger 
than 5 years and two (0·1%; both identiﬁ ed in the 2009 
survey) of 1408 individuals aged 5 years or older (mean 
age 34 years [SD 22·5; range 5–92]), carried H inﬂ uenzae 
type b in the nasopharynx.
To assess serological immunity, we tested available 
stored serum samples from children younger than 12 years 
from four convenience samples (367 samples from 1998 
and 2000, 253 samples from 2004–05, and 205 samples 
from 2007), and a further 438 samples from our age-
stratiﬁ ed, random sample of KHDSS children in 2009. 
The pattern of immunity in children in the community is 
shown in ﬁ gures 2 and 3 and the appendix. The proportion 
of children with an anti-PRP concentration of greater than 
1 mg/mL (the putative threshold for long-term protection 
from invasive H inﬂ uenzae type b disease) increased with 
age in the prevaccine surveys in 1998 and 2000, from very 
low proportions of infants (one [4%] of 24]) aged 
Figure 2: Children with anti-PRP concentrations of >1 μg/mL, by age group and survey year
Data for 1998 and 2000 combined (A), 2004–05 (B), 2007 (C), and 2009 (D). The proportion of children aged 4–7 months in (A) is 0%. Error bars show 95% CI. 
PRP=polyribosylribitol phosphate.
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4–7 months and 8–11 months (those at highest risk of 
invasive H inﬂ uenzae type b disease) up to 35 (61%; 95% CI 
48–74) of 57 children aged 9–12 years (ﬁ gure 2).18 After Hib 
vaccine intro duction, a large proportion of children had 
protective concentrations of antibody (92 [79%; 95% CI 
70–86] of 117 children aged 4–35 months had long-term 
protective anti-PRP concentrations in 2009) and 
the proportion with long-term protective anti-PRP 
concentrations did not start to decline until after 
36 months of age (ﬁ gure 2). We noted a similar pattern 
when assessing the geometric mean concentrations 
(appendix).
The proportions of children of various ages exceeding 
anti-PRP concentrations in the years before and after 
vaccine introduction are shown in the reverse cumulative 
distribution (RCD) curves (ﬁ gure 3). The proportions of 
children aged 4 months to 2 years exceeding anti-PRP 
concentrations of 0·15 μg/mL and 1 mg/mL were almost 
uniformly greater in the years after vaccine introduction 
than in the prevaccine surveys (ie, the RCD curves shift 
up and to the right after vaccine introduction). In children 
aged 3–4 years, serological protection declined in 2004–05, 
but by 2007, population immunity was greater than in 
prevaccine years. Children aged 5–12 years had a transient 
decline in serological protection during 2004–05 and 
2007, but the RCD curves suggest the same extent of 
population protection in 2009 as in prevaccine years.
Discussion
We report sustained control of paediatric invasive 
H inﬂ uenzae type b disease, to the point of near 
elimination, in Kiliﬁ , Kenya, in the 13 years after the 
introduction of Hib vaccine into the routine infant 
vaccination schedule without a booster dose. Kenya was 
one of three countries in Africa that were ﬁ rst to include 
the Hib vaccine in their routine childhood immunisation 
programme, and this study provides evidence of a robust 
and durable eﬀ ect of the vaccine programme. Worldwide, 
46 of 54 high-income countries give a booster dose of Hib 
vaccine, whereas booster doses are used by only six of 
78 low-income and lower-middle-income countries and 
22 of 57 upper-middle-income countries.4 This disparity is 
a reﬂ ection of the fact that support from Gavi, the Vaccine 
Alliance, for introduction of the Hib vaccine in the poorest 
countries of the world, which began in 2000, is aligned 
with the WHO recommendation for routine infant 
vaccination with Hib as a three-dose primary series.
After introduction of the Hib vaccine, a marked 
reduction in H inﬂ uenzae type b disease has been 
documented in many developed and developing regions; 
Figure 3: Reverse cumulative proportions of children with anti-PRP concentrations that exceed thresholds, by age group and survey year
Data for children aged 4–11 months (A) 1–2 years (B), 3–4 years (C), and 5–12 years (D). Vertical lines indicate thresholds for short-term (0·15 μg/mL) and long-term 
(1 μg/mL) protection against invasive H inﬂ uenzae type b disease.
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however, opportunities to examine the sustainability of 
the vaccine impact in the absence of a booster dose have 
been scarce.1 Our results are consistent with ﬁ ndings in 
western regions of The Gambia of near elimination of 
paediatric H inﬂ uenzae type b meningitis 14 years after 
introduction of Hib vaccine administered at 2, 3, and 
4 months of age and in the absence of a booster dose.8 As 
in The Gambia, our study occurred in a setting with high 
vaccine coverage: in the KHDSS, coverage with three 
doses of the Hib vaccine was 91% in children aged 
12 months in 2002, 88% in children aged 9–23 months in 
2004, 95% in children aged 12 months in 2007, and 93% in 
2013 in those aged 12–23 months resident in the KHDSS 
since birth who had vaccine cards available (Scott JAG, 
unpublished).19,20 Additional evidence of sustained disease 
control in the absence of a booster dose is provided by data 
from South America, where the incidence of H inﬂ uenzae 
type b meningitis 6–10 years after vaccination introduction 
was similar in four countries, two of which used a booster 
dose and two of which did not.21
By contrast, evidence of waning immunity has prompted 
three countries—the UK, Mexico, and South Africa—to 
add a booster dose of Hib vaccine, after they initially 
recommended only a primary series. In response to low 
levels of anti-PRP concentrations, persistence of 
H inﬂ uenzae type b nasopharyngeal carriage, and rising 
rates of invasive disease, the UK introduced a booster dose 
of Hib vaccine for children aged 12–15 months in 2006, 
10 years after introducing infant Hib vaccine with a catch-
up campaign but without a booster dose.5 In Mexico, in 
2006, results of a cross-sectional study showed that only 
40–50% of 110 children aged 12–23 months had anti-PRP 
concentrations greater than 1 mg/mL.7 92% of these 
children had received the full Hib vaccine primary course 
given as the combination pentavalent vaccine, the same 
combination vaccine as is used in Kenya. On the basis of 
these results, Mexico, an upper-middle-income country, 
introduced Hib booster vaccine in 2007. In 2010, 11 years 
after introducing Hib vaccine as a three-dose primary 
series, South Africa also introduced a booster dose of the 
combination vaccine containing Hib. Although the 
booster dose was primarily for polio prevention, it was 
hoped that the booster would reduce the number of Hib 
vaccine failures in South African children (135 [51%] of 
263 cases of invasive H inﬂ uenzae type b disease in 
2003–09 were classiﬁ ed as being the result of vaccine 
failures, of which 55% occurred in children aged 
18 months or older).22 In 2015, a resurgence of invasive 
H inﬂ uenzae type b disease was reported in eastern 
regions of The Gambia where coverage with three doses 
of Hib vaccine was 91% in children aged 12 months, 
suggesting that a three-dose primary series in the absence 
of a booster dose might not be providing sustained disease 
control in this setting.23 The reason for this resurgence 
was unclear, but the authors of the report speculated that 
it could have been related to waning immunity, continued 
transmission, or a change in malaria prevalence.
The reason a booster dose is needed to achieve sustained 
control of disease in some settings but not others remains 
unclear. Tetanus-toxoid-conjugated Hib vaccine is used 
widely in developing countries—both in settings with 
sustained control of H inﬂ uenzae type b disease and in 
those with evidence of waning immunity—so the vaccine 
formulation is unlikely to explain the diﬀ erent patterns of 
disease. Vaccinated individuals are less likely to be 
carriers of H inﬂ uenzae type b and are therefore less likely 
to transmit the infection. However, reductions in carriage 
and transmission also result in fewer opportunities for 
natural acquisition of anti-H inﬂ uenzae type b antibodies 
or for boosting of such antibodies. This might have been 
the reason anti-H inﬂ uenzae type b antibodies declined in 
adults after routine use of Hib vaccine in children in the 
UK.24 In The Gambia from 1997 to 2002, introduction and 
widespread use of Hib vaccine was associated with a 
decline in nasopharyngeal carriage of H inﬂ uenzae type b 
from 12% to 0·25% in children younger than 5 years.25 In 
2010, oropharyngeal H inﬂ uenzae type b carriage, as 
detected by culture, was estimated to be 0·9% in children 
aged 12–23 months in eastern regions of The Gambia.8 
This is slightly higher than the carriage prevalence 
detected by culture of nasopharyngeal swabs reported 
herein. Culture of oropharyngeal swabs and PCR-based 
methods might be more sensitive for the detection of 
H inﬂ uenzae type b than are nasopharyngeal swabs;26,27 
however, carriage in KHDSS residents was also low when 
PCR for H inﬂ uenzae type b was done on both 
oropharyngeal and nasopharyngeal swabs collected from 
children aged 2–59 months enrolled as controls in a 
multisite study of pneumonia aetiology in 2011–13 (three 
[<1%] of 856 children; Hammitt LL and Scott JAG, 
unpublished). Although older children and adults can 
serve as a reservoir for transmission, the prevalence of 
H inﬂ uenzae type b carriage was very low in these age 
groups in Kiliﬁ . On the basis of these data, the 
opportunities for natural boosting in Kiliﬁ  are rare, as is 
the risk of exposure.
In Kiliﬁ , in the years after vaccine introduction, naturally 
acquired antibody has been replaced by vaccine-induced 
antibody. For infants and young children, this has meant 
greater serological protection, with 79% (95% CI 59–92) of 
children aged 4–11 months (historically at greatest risk of 
invasive disease) now having concentrations greater than 
1 mg/mL, the threshold associated with long-term 
H inﬂ uenzae type b-speciﬁ c protection.18 Older children, 
who in the prevaccine era had naturally acquired immunity, 
went through a transitional period (2004–05 and 2007) 
during which both geometric mean concentrations and 
proportions exceeding protective thresholds were lower 
than in the prevaccine era. As surveys of older children 
started to include those who had been vaccinated, and 
vaccine-induced antibody was persisting into late 
childhood, measures for children aged 5–12 years resumed 
their prevaccine levels by 2009. In essence, the vaccine has 
led to improvements in population immunity in the 
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youngest, highest-risk age groups without compromising 
immunity in older children. The low number of serosurvey 
participants in the youngest age groups is a limitation of 
these data. Although the 2009 survey participants were 
selected at random from KHDSS records, earlier surveys 
were convenience samples, which might have resulted in 
imbalances in representation of children in KHDSS as a 
whole. Additionally, the longer duration of freezing could 
have degraded antibody in older samples. These limitations 
notwithstanding, these results are promising for the 
prospect of continued eﬀ ectiveness of Hib vaccine against 
invasive disease in older children and for maintenance of 
herd immunity in this setting. However, continued 
observation is needed, because the proportion of older 
children (aged 9–12 years) with anti-PRP concentrations 
greater than 1 mg/mL in Kiliﬁ  in 2009 (28 [45%] of 
62 children) was similar to eastern regions of The Gambia 
(55% of 9–14 year-olds), where a resurgence in disease has 
been noted.
Our immunogenicity data are similar to other studies’ 
data from low-income or lower-middle-income countries. 
In vaccine trials in Niger and Nepal, 83–88% and 100% of 
infants, respectively, had post-primary vaccination 
concentrations of anti-PRP above 1 mg/mL, declining to 
67–75% and 64%, respectively, by late infancy.28,29 In Mali, 
2 years after vaccine introduction and with coverage at 
81%, 82% of infants aged 6–7 months had anti-PRP 
concentrations greater than 1 mg/mL.30 In the same 
setting the following year, antibody decline did not begin 
until after 2 years of age.31 Our results also lend support to 
the previously observed ﬁ ndings that children in 
developing countries generate higher anti-PRP 
concentrations in response to vaccination than those in 
developed countries such as the UK.32 Proposed reasons 
for this include higher background environmental 
H inﬂ uenzae type b exposure in developing countries and 
exposure to bacterial polysaccharides that cross-react with 
the PRP capsular polysaccharide of H inﬂ uenzae type b.33–36 
Exposure to potentially cross-reactive organisms such as 
Escherichia coli or serogroup 6 pneumococci is likely to be 
higher in developing countries without access to 
improved water and sanitation or with higher overall 
pneumococcal carriage prevalence and density than in 
high-income or middle-income settings.13,37–39 The level 
and eﬀ ects of this exposure could change with 
improvements in water and sanitation and expanding 
use of pneumococcal conjugate vaccines. Continued 
surveillance will monitor whether eﬀ ective control of 
disease persists or whether shifts in epidemiology (eg, 
disease occurring in older children, fewer opportunities 
for natural boosting) will necessitate a booster dose.
The ﬁ ndings reported herein do not address the 
possible beneﬁ t of a booster dose of Hib vaccine in 
settings with diﬀ erent epidemiological characteristics 
from Kiliﬁ  (eg, higher HIV prevalence, lower vaccine 
coverage, exposure to highly unvaccinated populations 
that might have high rates of carriage). Because the 
reasons why some settings require a booster dose of Hib 
vaccine to maintain control of disease and others do not 
are not well understood, local epidemiological data is 
vital to guide vaccine policy. In the absence of long-
standing surveillance for invasive H inﬂ uenzae type b 
disease, low H inﬂ uenzae type b carriage prevalence in 
large studies that include both children and adults and 
use sensitive methods of detection, or high prevalence of 
protective antibody concentrations throughout the ages 
of highest risk for H inﬂ uenzae type b disease, would 
provide evidence of ongoing protection.
Over the past 25 years, 189 countries, including 
73 countries eligible for support from Gavi, the Vaccine 
Alliance, have introduced a Hib-containing vaccine into 
their national immunisation programme for children. A 
booster dose of Hib vaccine is recommended in most 
high-income countries, whereas most low-income 
countries have followed the WHO EPI schedule, which 
does not include a booster dose. In this study, we found 
that use of Hib vaccine according to the EPI schedule led 
to near elimination of paediatric invasive H inﬂ uenzae 
type b disease, with no evidence of resurgent disease in 
older children in whom immunity might be expected to 
wane without a booster dose. Indeed, immunogenicity 
data show that immunity persists through the age of 
greatest risk of disease for most children and that 
antibody concentrations in older children, although lower 
than in young children, are similar to concentrations 
reported in the prevaccine era. In sum, we found no 
evidence to support introduction of a booster dose of Hib 
vaccine into the Kenyan EPI at this time.
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